Here you'll find resources to better understand next-generation sequencing and its role in precision oncology, as well as events you can attend in person and online to stay current with advances in NGS.
NGS has emerged as the platform of choice for tumor genomic profiling. This technology offers several advantages over traditional methods. With NGS, multiple cancer biomarkers can be assessed simultaneously in a single test to quickly reveal a full molecular profile, all while preserving tissue.
Learn how NGS technology advancements are bringing new possibilities to the future of cancer care.
Bring precision oncology closer to your patients and empower your care team with in-house molecular testing
Consider the key advantages for evaluating the future of multi-biomarker testing in your institution.
Come out and meet us at events to see our latest solutions, meet our product experts, and hear from our customers.
Historically, cancer treatment followed a one-size-fits-all model, where therapies were selected based on tumor site alone. As our understanding of cancer biology grows, therapy decisions are increasingly based on specific biomarkers and genetic alterations present in an individual’s cancer genome.
NGS has emerged as the platform of choice for tumor genomic profiling. This technology offers several advantages over traditional, iterative methods, which are sample, time, labor, and cost intensive. With NGS, multiple cancer biomarkers can be assessed simultaneously in a single test to quickly reveal a full molecular profile, all while preserving tissue. Clinicians and cancer patients no longer have to wait weeks for results—now targeted, potentially life-saving, first-line therapies can be initiated sooner.
Advancing precision oncology involves matching targeted therapies to an individual’s and their cancer’s specific genomic profile—NGS provides the needed genomic intelligence to facilitate this. Patients can be readily paired to the appropriate targeted therapy or to applicable clinical trials of developing therapies.
1) During the initial diagnosis phase, an NGS test is ordered with the specified biomarker panel.
NGS is a highly scalable technology—the spectrum of analysis can extend from a small number of genes to an entire genome, depending upon the goal.
Whole-genome sequencing (WGS) and whole-exome sequencing (WES) identify every DNA base across the genome and exome, respectively. Yielding massive data sets, these methods are ideal for research and discovery efforts.
Whole-transcriptome sequencing identifies coding and noncoding RNA to assess variations and gene expression levels across the entire transcriptome. This method is also better suited for research and discovery efforts.
While the value of WGS and WES has been recognized in studying oncology, these methods are impractical in the clinical arena due to costs, long turn-around time to results (weeks), and the complexities of data storage, analysis, and interpretation.
Targeted sequencing panels profile a small set of genes that are curated for a specific application or disease. Featuring actionable biomarkers, these panels are commonly used in clinical applications as they help inform the diagnosis, treatment, and monitoring of individual patient disease.
For clinicians and patients
For in-house labs
NGS has only just begun to inform the continuum of cancer care. The promise of precision oncology will be realized as more and more community hospital labs adopt in-house NGS and clinicians are empowered to leverage these essential genomic insights for targeted care and better outcomes.